GC Green Cross, Full Free Supply of COVID-19 Plasma Therapy

[Asia Economy Reporter Cho Hyun-ui] GC Green Cross announced on the 18th that it will provide its plasma treatment for COVID-19, 'GC5131A,' currently under development, free of charge to domestic patients.

GC Green Cross plans to bear all costs from development to commercialization, excluding government subsidies. It will supply the treatment entirely free of charge without any conditions such as quantity limits.

This is the first time a pharmaceutical company has decided to provide a COVID-19 treatment completely free of charge. It signifies a willingness to endure financial losses beyond foregoing profits. The company requested shareholders' understanding and consent regarding this decision aimed at creating a stable future rather than short-term profits through a shareholder letter on the same day.

Huh Eun-cheol, CEO of GC Green Cross, said, "Medicines used to treat unprecedented infectious diseases should be dedicated solely to stabilizing public health," adding, "The plasma treatment platform created by harnessing the power of the Korean people who overcame COVID-19 holds value beyond monetary terms."

Meanwhile, GC5131A is a medicine made by extracting various effective immune antibodies from the plasma of recovered COVID-19 patients. It is classified as a medicine that can be administered most rapidly in the event of a new infectious disease outbreak.

This content was produced with the assistance of AI translation services.